Vascular endothelial growth factor inhibitors in malignant gliomas

Targeted Oncology

Volumn 5, Issue 3, 2010, Pages 167-174

  Brastianos, Priscilla K ^a,b   Batchelor, Tracy T ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Glioblastoma; Malignant glioma; Vascular endothelial growth factor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CORTICOSTEROID; CT 322; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; PAZOPANIB; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VATALANIB; VOTRIENT;

ADJUVANT THERAPY; BLEEDING; BRAIN EDEMA; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; TUMOR BLEEDING; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78049292770     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0158-1     Document Type: Review

References (84)

1. H Ohgaki P Kleihues 2005 Epidemiology and etiology of gliomas Acta Neuropathol 109 93 108 10.1007/s00401-005-0991-y 15685439 (Pubitemid 40287792)
2. H Ohgaki 2009 Epidemiology of brain tumors Methods Mol Biol 472 323 342 1:CAS:528:DC%2BD1cXhsVeqt7fL 10.1007/978-1-60327-492-0-14 19107440
3. F Winkler SV Kozin RT Tong, et al. 2004 Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 553 563 1:CAS:528:DC%2BD2MXktVantw%3D%3D 15607960
4. O Kargiotis JS Rao AP Kyritsis 2006 Mechanisms of angiogenesis in gliomas J Neurooncol 78 281 293 1:CAS:528:DC%2BD28Xpt1ylt7Y%3D 10.1007/s11060-005-9097- 6 16554966 (Pubitemid 44018823)
5. RK Jain 2001 Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 987 989 1:CAS:528: DC%2BD3MXmvFOmsrc%3D 10.1038/nm0901-987 11533692 (Pubitemid 32937367)
6. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 1:CAS:528:DC%2BD2MXnvFar 10.1126/science.1104819 15637262 (Pubitemid 40093472)
7. RT Tong Y Boucher SV Kozin, et al. 2004 Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 3731 3736 1:CAS:528:DC%2BD2cXksVKgur8%3D 10.1158/0008-5472.CAN-04-0074 15172975 (Pubitemid 38697278)
8. RK Jain E di Tomaso DG Duda, et al. 2007 Angiogenesis in brain tumours Nat Rev Neurosci 8 610 622 1:CAS:528:DC%2BD2sXnvFKntbk%3D 10.1038/nrn2175 17643088 (Pubitemid 47093931)
9. RK Jain RT Tong LL Munn 2007 Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model Cancer Res 67 2729 2735 1:CAS:528:DC%2BD2sXivV2nsLw%3D 10.1158/0008-5472.CAN-06-4102 17363594 (Pubitemid 46548961)
10. G Helmlinger F Yuan M Dellian RK Jain 1997 Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation Nat Med 3 177 182 1:CAS:528:DyaK2sXpsVOktw%3D%3D 10.1038/nm0297-177 9018236 (Pubitemid 27064702)
11. F Yuan HA Salehi Y Boucher, et al. 1994 Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows Cancer Res 54 4564 4568 1:STN:280:DyaK2czktVGksA%3D%3D 8062241
12. Y Boucher M Leunig RK Jain 1996 Tumor angiogenesis and interstitial hypertension Cancer Res 56 4264 4266 1:CAS:528:DyaK28XlslGgtL4%3D 8797602
13. R Rampling G Cruickshank AD Lewis SA Fitzsimmons P Workman 1994 Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors Int J Radiat Oncol Biol Phys 29 427 431 1:CAS:528: DyaK2cXlvFGitL4%3D 8005794 (Pubitemid 24187904)
14. Y Rong DL Durden EG Van Meir DJ Brat 2006 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis J Neuropathol Exp Neurol 65 529 539 10.1097/00005072-200606000-00001 16783163
15. J Holash PC Maisonpierre D Compton, et al. 1999 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994 1998 1:CAS:528:DyaK1MXktVWntrY%3D 10.1126/science.284.5422.1994 10373119 (Pubitemid 29309448)
16. GD Yancopoulos S Davis NW Gale, et al. 2000 Vascular-specific growth factors and blood vessel formation Nature 407 242 248 1:CAS:528: DC%2BD3cXmvVSlsrY%3D 10.1038/35025215 11001067
17. D Zagzag R Amirnovin MA Greco, et al. 2000 Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis Lab Invest 80 837 849 1:STN:280:DC%2BD3czjs1SrsA%3D%3D 10879735
18. DG Duda KS Cohen SV Kozin, et al. 2006 Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors Blood 107 2774 2776 1:CAS:528:DC%2BD28XjtlKlu7s%3D 10.1182/blood-2005-08-3210 16339405
19. S Yano H Shinohara RS Herbst, et al. 2000 Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis Cancer Res 60 4959 4967 1:CAS:528: DC%2BD3cXmsFWhsbk%3D 10987313
20. KH Plate G Breier HA Weich W Risau 1992 Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 845 848 1:CAS:528:DyaK38XmsV2gsb8%3D 10.1038/359845a0 1279432
21. NO Schmidt M Westphal C Hagel, et al. 1999 Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis Int J Cancer 84 10 18 1:CAS:528:DyaK1MXht1Cqt78%3D 10.1002/(SICI)1097-0215(19990219)84: 1<10::AID-IJC3>3.0.CO;2-L 9988225 (Pubitemid 29059101)
22. R Abounader J Laterra 2005 Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis Neuro Oncol 7 436 451 1:CAS:528: DC%2BD2MXht1SisLvO 10.1215/S1152851705000050 16212809 (Pubitemid 41555616)
23. DF Stefanik LR Rizkalla A Soi SA Goldblatt WM Rizkalla 1991 Acidic and basic fibroblast growth factors are present in glioblastoma multiforme Cancer Res 51 5760 5765 1:CAS:528:DyaK3MXmsFeju7s%3D 1717153
24. RS Kerbel 2008 Tumor angiogenesis N Engl J Med 358 2039 2049 1:CAS:528:DC%2BD1cXlsFyrtro%3D 10.1056/NEJMra0706596 18463380 (Pubitemid 351656458)
25. D Fukumura S Kashiwagi RK Jain 2006 The role of nitric oxide in tumour progression Nat Rev Cancer 6 521 534 1:CAS:528:DC%2BD28XmtFehu7Y%3D 10.1038/nrc1910 16794635 (Pubitemid 43980541)
26. D Fukumura L Xu Y Chen, et al. 2001 Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo Cancer Res 61 6020 6024 1:CAS:528:DC%2BD3MXmt12ktrc%3D 11507045
27. K Lamszus O Heese M Westphal 2004 Angiogenesis-related growth factors in brain tumors Cancer Treat Res 117 169 190 1:CAS:528:DC%2BD2cXptFKiu7w%3D 15015561
28. D Mukhopadhyay L Tsiokas VP Sukhatme 1995 Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression Cancer Res 55 6161 6165 1:CAS:528:DyaK2MXhtVShtLzE 8521408
29. CK Goldman J Kim WL Wong, et al. 1993 Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology Mol Biol Cell 4 121 133 1:CAS:528:DyaK3sXitFSnsLs%3D 7680247
30. J Weissenberger JP Steinbach G Malin, et al. 1997 Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice Oncogene 14 2005 2013 1:CAS:528:DyaK2sXjsVKiu70%3D 10.1038/sj.onc.1201168 9160879
31. B Millauer LK Shawver KH Plate W Risau A Ullrich 1994 Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 367 576 579 1:CAS:528:DyaK2cXhs1Sgt7w%3D 10.1038/367576a0 8107827
32. M Shibuya L Claesson-Welsh 2006 Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis Exp Cell Res 312 549 560 1:CAS:528:DC%2BD28XhvVWltbo%3D 10.1016/j.yexcr.2005.11.012 16336962 (Pubitemid 43290332)
33. D Hanahan 1997 Signaling vascular morphogenesis and maintenance Science 277 48 50 1:CAS:528:DyaK2sXksVyhtrk%3D 10.1126/science.277.5322.48 9229772 (Pubitemid 27450640)
34. J Oliner H Min J Leal, et al. 2004 Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 507 516 1:CAS:528:DC%2BD2cXhtVGlurjP 10.1016/j.ccr.2004.09.030 15542434 (Pubitemid 39469986)
35. J Ridgway G Zhang Y Wu, et al. 2006 Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis Nature 444 1083 1087 1:CAS:528:DC%2BD28XhtlemtLnP 10.1038/nature05313 17183323 (Pubitemid 46018529)
36. I Noguera-Troise C Daly NJ Papadopoulos, et al. 2006 Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis Nature 444 1032 1037 1:CAS:528:DC%2BD28XhtlemtLnL 10.1038/nature05355 17183313 (Pubitemid 46018516)
37. J Folkman 2007 Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 273 286 1:CAS:528:DC%2BD2sXjs1SisL4%3D 10.1038/nrd2115 17396134 (Pubitemid 46505878)
38. TT Batchelor AG Sorensen E di Tomaso, et al. 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 1:CAS:528: DC%2BD2sXhtFClsLc%3D 10.1016/j.ccr.2006.11.021 17222792 (Pubitemid 46075199)
39. WS Kamoun CD Ley CT Farrar, et al. 2009 Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 15 2542 2552 1:CAS:528:DC%2BD1MXmvVOhsbY%3D 10.1200/JCO.2008.19.9356 19332720
40. WB Pope A Lai P Nghiemphu P Mischel TF Cloughesy 2006 MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy Neurology 66 1258 1260 1:CAS:528:DC%2BD28XjtFOrtLs%3D 10.1212/01.wnl.0000208958.29600.87 16636248 (Pubitemid 43739717)
41. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 1:CAS:528:DC%2BD2sXhvF2htr8%3D 10.1158/1078-0432.CCR-06-2309 17317837 (Pubitemid 46424067)
42. C Conrad H Friedman D Reardon, et al. 2004 A phase I/II trial of single-agent PTK787/ZK 22584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma (BGM) [abstract 1512] ASCO Annu Meeting Proc (Post-Meeting Edition) 22 Suppl 1512
43. J Drevs R Muller-Driver C Wittig, et al. 2002 PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging Cancer Res 62 4015 4022 1:CAS:528:DC%2BD38XlsV2lsLg%3D 12124335
44. C Calabrese H Poppleton M Kocak, et al. 2007 A perivascular niche for brain tumor stem cells Cancer Cell 11 69 82 1:CAS:528:DC%2BD2sXhtFClsLY%3D 10.1016/j.ccr.2006.11.020 17222791 (Pubitemid 46054518)
45. S Bao Q Wu S Sathornsumetee, et al. 2006 Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor Cancer Res 66 7843 7848 1:CAS:528:DC%2BD28XotFWqsb8%3D 10.1158/0008-5472.CAN-06-1010 16912155 (Pubitemid 44299144)
46. V Stark-Vance 2005 Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma Neuro Oncol 7 369
47. AD Norden GS Young K Setayesh, et al. 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 1:CAS:528:DC%2BD1cXitlyqs7o%3D 10.1212/01.wnl.0000304121.57857.38 18316689
48. S Guiu S Taillibert O Chinot, et al. 2008 Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study Rev Neurol (Paris) 164 588 594 1:STN:280: DC%2BD1cvotl2ntA%3D%3D
49. C Hess V Vuong I Hegyi, et al. 2001 Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth Br J Cancer 85 2010 2016 1:CAS:528:DC%2BD38XhsVWmsrw%3D 10.1054/bjoc.2001.2166 11747347
50. SA Wagner A Desjardins DA Reardon, et al. 2008 Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas J Clin Oncol 26 2021 10.1200/JCO.2008.17.3674
51. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 1:CAS:528:DC%2BD2sXhtlCgsLjF 10.1200/JCO.2007.12.2440 17947719 (Pubitemid 350086473)
52. W Chen S Delaloye DH Silverman, et al. 2007 Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study J Clin Oncol 25 4714 4721 1:CAS:528:DC%2BD2sXhtlCgsLjL 10.1200/JCO.2006.10.5825 17947718 (Pubitemid 350086472)
53. T Cloughesy MD Prados PY Wen, et al. 2008 A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) J Clin Oncol 26 2010b
54. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
55. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
56. HS Friedman MD Prados PY Wen, et al. 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721 19720927
57. HS Friedman MD Prados PY Wen, et al. 2010 Reply to W. Wick et al J Clin Oncol 28 e190 e192 10.1200/JCO.2009.26.9472
58. T Cloughesy J Vredenburgh B Day A Das AH Friedman 2010 Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study J Clin Oncol 28 2008 10.1200/JCO.2009.25.8988
59. W Wick M Weller MJ Van den Bent R Stupp 2010 Bevacizumab and recurrent malignant gliomas: a European perspective J Clin Oncol 28 e188 e189 10.1200/JCO.2009.26.9027 20159801
60. PR Wachsberger R Burd C Cardi, et al. 2007 VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma Int J Radiat Oncol Biol Phys 67 1526 1537 1:CAS:528:DC%2BD2sXjs1Oisr4%3D 17234361
61. J Holash S Davis N Papadopoulos, et al. 2002 VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci USA 99 11393 11398 1:CAS:528:DC%2BD38XmslSmu7s%3D 10.1073/pnas.172398299 12177445 (Pubitemid 34920936)
62. JF De Groot PY Wen K Lamborn, et al. 2008 Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 J Clin Oncol 26 2020 10.1200/JCO.2007.12.3117
63. TT Batchelor DG Duda E di Tomaso, et al. 2010 Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 15S 2043
64. JN Rich S Sathornsumetee ST Keir, et al. 2005 ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors Clin Cancer Res 11 8145 8157 1:CAS:528:DC%2BD2MXht1entrzJ 10.1158/1078-0432.CCR- 05-0319 16299247 (Pubitemid 41698759)
65. J Drappatz AD Norden ET Wong, et al. 2010 Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma Int J Radiat Oncol Biol Phys 10.1016/j.ijrobp. 2009.07.1741 20137866
66. RH Goldbrunner M Bendszus J Wood, et al. 2004 PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization Neurosurgery 55 426 432 15271251 discussion 432
67. L Liu Y Cao C Chen, et al. 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 11851 11858 1:CAS:528: DC%2BD28Xhtlagu73F 10.1158/0008-5472.CAN-06-1377 17178882 (Pubitemid 46094197)
68. B Escudier T Eisen WM Stadler, et al. 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 1:CAS:528: DC%2BD2sXksVKitg%3D%3D 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
69. JM Llovet S Ricci V Mazzaferro, et al. 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514
70. EP Jane DR Premkumar IF Pollack 2006 Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells J Pharmacol Exp Ther 319 1070 1080 1:CAS:528:DC%2BD28Xht1yltL%2FM 10.1124/jpet.106.108621 16959960
71. Nabors L, Rosenfeld M, Chamberlain M et al (2007) A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 2058
72. RJ Motzer TE Hutson P Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 10.1056/NEJMoa065044 17215529 (Pubitemid 46089672)
73. GD Demetri AT van Oosterom CR Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 1:CAS:528:DC%2BD28XhtVOrtL%2FL 10.1016/S0140-6736(06)69446-4 17046465 (Pubitemid 44528723)
74. FM Iwamoto TN Kreisl L Kim, et al. 2010 Phase II trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas Cancer 116 1776 1782 1:CAS:528:DC%2BC3cXkvFOns7k%3D 10.1002/cncr.24957 20143438
75. D Schiff D Reardon S Kesari, et al. 2010 Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM) J Clin Oncol 28 2011
76. HM Verheul HM Pinedo 2007 Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 475 485 1:CAS:528:DC%2BD2sXls1Kjsb4%3D 10.1038/nrc2152 17522716 (Pubitemid 46809172)
77. PL Nghiemphu RM Green WB Pope A Lai TF Cloughesy 2008 Safety of anticoagulation use and bevacizumab in patients with glioma Neuro Oncol 10 355 360 10.1215/15228517-2008-009 18436627
78. J Bartolomeo A Norden J Drappatz, et al. 2010 Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients J Clin Oncol 28 2043
79. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592 603 1:CAS:528:DC%2BD1cXovV2lsrk%3D 10.1038/nrc2442 18650835
80. MJ van den Bent MA Vogelbaum PY Wen DR Macdonald SM Chang 2009 End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria J Clin Oncol 27 2905 2908 10.1200/JCO.2009.22.4998 19451418
81. PY Wen DR Macdonald DA Reardon, et al. 2010 Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 1963 1972 10.1200/JCO.2009.26.3541 20231676
82. N Hylton 2006 Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker J Clin Oncol 24 3293 3298 1:CAS:528:DC%2BD28Xot1yhsrw%3D 10.1200/JCO.2006.06.8080 16829653 (Pubitemid 46622069)
83. T Barrett M Brechbiel M Bernardo PL Choyke 2007 MRI of tumor angiogenesis J Magn Reson Imaging 26 235 249 10.1002/jmri.20991 17623889 (Pubitemid 47257720)
84. G Popperl FW Kreth J Herms, et al. 2006 Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 47 393 403 16513607